Literature DB >> 24638135

Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.

Yan-Jiang Wang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638135     DOI： 10.1038/nrneurol.2014.44

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

Review 3.  Immunotherapy for Alzheimer disease: the challenge of adverse effects.

Authors:  Yu-Hui Liu; Brian Giunta; Hua-Dong Zhou; Jun Tan; Yan-Jiang Wang
Journal:  Nat Rev Neurol       Date:  2012-07-03       Impact factor: 42.937

4.  Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Authors:  Wagner Zago; Sally Schroeter; Teresa Guido; Karen Khan; Peter Seubert; Ted Yednock; Dale Schenk; Keith M Gregg; Dora Games; Frédérique Bard; Gene G Kinney
Journal:  Alzheimers Dement       Date:  2013-04-11       Impact factor: 21.566

5.  Molecular basis for passive immunotherapy of Alzheimer's disease.

Authors:  Anna S Gardberg; Lezlee T Dice; Susan Ou; Rebecca L Rich; Elizabeth Helmbrecht; Jan Ko; Ronald Wetzel; David G Myszka; Paul H Patterson; Chris Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

Authors:  Ronald B Demattos; Jirong Lu; Ying Tang; Margaret M Racke; Cindy A Delong; John A Tzaferis; Justin T Hole; Beth M Forster; Peter C McDonnell; Feng Liu; Robert D Kinley; William H Jordan; Michael L Hutton
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

7.  Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

Authors:  Kaoru Yamada; Chiori Yabuki; Peter Seubert; Dale Schenk; Yukiko Hori; Sumio Ohtsuki; Tetsuya Terasaki; Tadafumi Hashimoto; Takeshi Iwatsubo
Journal:  J Neurosci       Date:  2009-09-09       Impact factor: 6.167

Review 8.  Deciphering the mechanism underlying late-onset Alzheimer disease.

Authors:  Dimitrije Krstic; Irene Knuesel
Journal:  Nat Rev Neurol       Date:  2012-11-27       Impact factor: 42.937

9.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

10.  Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

Authors:  Simon J Henderson; Christin Andersson; Rajesh Narwal; Juliette Janson; Tom J Goldschmidt; Paulina Appelkvist; Anna Bogstedt; Ann-Charlott Steffen; Ulrich Haupts; Jan Tebbe; Per Ola Freskgård; Lutz Jermutus; Matthew Burrell; Susan B Fowler; Carl I Webster
Journal:  Brain       Date:  2013-11-20       Impact factor: 13.501
  10 in total
  20 in total

1.  Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.

Authors:  Shu-Sheng Jiao; Xiu-Qing Yao; Yu-Hui Liu; Qing-Hua Wang; Fan Zeng; Jian-Jun Lu; Jia Liu; Chi Zhu; Lin-Lin Shen; Cheng-Hui Liu; Ye-Ran Wang; Gui-Hua Zeng; Ankit Parikh; Jia Chen; Chun-Rong Liang; Yang Xiang; Xian-Le Bu; Juan Deng; Jing Li; Juan Xu; Yue-Qin Zeng; Xiang Xu; Hai-Wei Xu; Jin-Hua Zhong; Hua-Dong Zhou; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance.

Authors:  Yu-Hui Liu; Yang Xiang; Ye-Ran Wang; Shu-Sheng Jiao; Qing-Hua Wang; Xian-Le Bu; Chi Zhu; Xiu-Qing Yao; Brian Giunta; Jun Tan; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-08-14       Impact factor: 5.590

Review 3.  The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial.

Authors:  Kun Xuan; Tianming Zhao; Guangbo Qu; Haixia Liu; Xin Chen; Yehuan Sun
Journal:  Neurol Sci       Date:  2020-01-13       Impact factor: 3.307

Review 4.  Dantrolene, a treatment for Alzheimer disease?

Authors:  Li Liang; Huafeng Wei
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

Review 5.  Targeting β-amyloid plaques and oligomers: development of near-IR fluorescence imaging probes.

Authors:  Hongwu Liu; Jian Yang; Letian Wang; Yungen Xu; Siyuan Zhang; Jie Lv; Chongzhao Ran; Yuyan Li
Journal:  Future Med Chem       Date:  2017-01-27       Impact factor: 3.808

Review 6.  Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.

Authors:  Yu-Hui Liu; Ye-Ran Wang; Yang Xiang; Hua-Dong Zhou; Brian Giunta; Noralyn B Mañucat-Tan; Jun Tan; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

7.  Single chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.

Authors:  Ying Zhang; Hai-Qiang Yang; Fang Fang; Lin-Lin Song; Yue-Ying Jiao; He Wang; Xiang-Lei Peng; Yan-Peng Zheng; Jun Wang; Jin-Sheng He; Tao Hung
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

8.  Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.

Authors:  Yang Xiang; Xian-Le Bu; Yu-Hui Liu; Chi Zhu; Lin-Lin Shen; Shu-Sheng Jiao; Xiao-Yan Zhu; Brian Giunta; Jun Tan; Wei-Hong Song; Hua-Dong Zhou; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Acta Neuropathol       Date:  2015-09-12       Impact factor: 17.088

Review 9.  Towards Personalized Intervention for Alzheimer's Disease.

Authors:  Xing Peng; Peiqi Xing; Xiuhui Li; Ying Qian; Fuhai Song; Zhouxian Bai; Guangchun Han; Hongxing Lei
Journal:  Genomics Proteomics Bioinformatics       Date:  2016-09-28       Impact factor: 7.691

Review 10.  Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.

Authors:  Bin-Lu Sun; Yang Chen; Dong-Yu Fan; Chi Zhu; Fan Zeng; Yan-Jiang Wang
Journal:  Sci China Life Sci       Date:  2020-10-23       Impact factor: 6.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.